Latest Hotspot

European regulators have approved UCB's ZILBRYSQ® (zilucoplan) for adult generalized Myasthenia Gravis treatment

12 December 2023
3 min read

Global biopharma leader UCB has received a green light from the European Commission (EC) to introduce ZILBRYSQ® (zilucoplan) into the market. This approval endorses the drug's use in combination with traditional treatments, specifically aimed at managing adult patients diagnosed with generalized myasthenia gravis who have tested positive for anti-acetylcholine receptor antibodies.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Zilucoplan emerges as the inaugural subcutaneous, once-a-day, targeted peptide modulator for gMG, precisely inhibiting the complement component 5 (C5), and stands as the sole C5 modulator sanctioned for self-injection by gMG patients over the age of 18 with AChR antibodies.

Through its precise bimodal action, zilucoplan mitigates damage at the neuromuscular junction caused by the complement system. Advantages of self-injection via the subcutaneous route encompass a reduction in travel time to healthcare facilities, minimized disruption to employment commitments, and an enhancement in patient autonomy.

European endorsement for zilucoplan is underpinned by robust safety and effectiveness outcomes from the RAISE trial, whose findings were detailed in The Lancet Neurology during May 2023. The pivotal study was a multi-site, phase 3, placebo-controlled, double-blind, randomized trial designed to evaluate zilucoplan's safety, efficacy, and tolerability among adult gMG patients positive for anti-acetylcholine receptor antibodies.

Zilucoplan's green light in Europe follows earlier regulatory approvals by the FDA for treating adult patients with gMG who are AChR antibody-positive and by the Japanese Ministry of Health, Labour and Welfare for gMG treatment in adults poorly responsive to steroids or other immunotherapy agents.

The green signal issued by the EC extends across all member countries of the EU and includes the European Economic Area nations of Iceland, Liechtenstein, and Norway. UCB aspires to expedite the delivery of zilucoplan to patients and expects to initiate distribution across Europe starting in the early part of 2024..

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of December 12, 2023, there are 46 investigational drugs for the C5 target, including 75 indications, 69 R&D institutions involved, with related clinical trials reaching 370, and as many as 197099 patents.

Zilucoplan is currently under review by the Australian Therapeutic Goods Administration and Health Canada for the treatment of adults with gMG. Responses from regulatory agencies to these submissions are expected between H2 2023 and H2 2024. Orphan designation for zilucoplan was granted by the FDA in 2019 for the treatment of myasthenia gravis.

图形用户界面, 文本, 应用程序

描述已自动生成

Deciphering Menin Inhibitors and Keeping Up with Their Recent Developments
Deciphering Menin Inhibitors and Keeping Up with Their Recent Developments
12 December 2023
Menin inhibitors are drugs that target the menin protein, crucial for regulating gene expression. The future of menin inhibitors is promising, with potential applications in treating various types of cancer.
Read →
What Retrieval Methods Can be Used in the CAR-T Field to Find More Comprehensive Technical Materials and Patent Information? (Part II)
Bio Sequence
3 min read
What Retrieval Methods Can be Used in the CAR-T Field to Find More Comprehensive Technical Materials and Patent Information? (Part II)
12 December 2023
In the CAR-T field, we can perform comprehensive data retrieval of CAR-T in two major parts: antibody search and CAR expression cassette design.
Read →
Sana Biotech's SC291, an off-the-shelf CAR T targeting CD19, undetected by immune system in initial clinical results
Latest Hotspot
3 min read
Sana Biotech's SC291, an off-the-shelf CAR T targeting CD19, undetected by immune system in initial clinical results
12 December 2023
Sana Biotechnology Releases Initial Clinical Findings Demonstrating SC291, an Off-the-Shelf CAR T Treatment Targeting CD19, Remains Undetected by a Functional Immune System.
Read →
Benitec Biopharma begins early trial dosing for BB-301, its genetic therapy for Oculopharyngeal Muscular Dystrophy
Latest Hotspot
3 min read
Benitec Biopharma begins early trial dosing for BB-301, its genetic therapy for Oculopharyngeal Muscular Dystrophy
8 December 2023
Benitec Biopharma has reported initial dosing in an early-stage trial for its genetic treatment prospect, BB-301, aimed at tackling Oculopharyngeal Muscular Dystrophy.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.